Search

Your search keyword '"standardized fluorescence molecular endoscopy methodology"' showing total 3 results
Start Over Descriptor "standardized fluorescence molecular endoscopy methodology"
3 results on '"standardized fluorescence molecular endoscopy methodology"'

1. C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies

Author

Max J. H. Witjes, Steven J de Jongh, Gooitzen M. van Dam, Gursah Kats-Ugurlu, F. J. Voskuil, Iris Schmidt, Gert Jan Meersma, Dominic J. Robinson, Wouter B. Nagengast, Arend Karrenbeld, Jessie Westerhof, Otorhinolaryngology and Head and Neck Surgery, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Microbes in Health and Disease (MHD), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Esophageal Neoplasms, IMAGING AGENTS, Biopsy, Medicine (miscellaneous), EMI-137 targeting c-Met, 03 medical and health sciences, Barrett Esophagus, Barrett's esophagus, 0302 clinical medicine, In vivo, ADENOMAS, medicine, Fluorescence microscope, Humans, Prospective Studies, Esophagus, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Aged, business.industry, standardized fluorescence molecular endoscopy methodology, Middle Aged, Proto-Oncogene Proteins c-met, medicine.disease, CANCER, Structured roadmap, 030104 developmental biology, medicine.anatomical_structure, Immunohistochemistry, Neoplastic cell, 030211 gastroenterology & hepatology, Histopathology, Female, Nuclear medicine, business, Ex vivo, Research Paper
Abstract

Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a 'red-flag' endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett's Esophagus (BE) and report several outcome parameters for early phase FME studies. Methods: FME was performed in 15 Barrett's neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 μg/cm BE (n=1) or 100 μg/cm BE (n=4). Fluorescence was visualized in vivo, quantified in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. Results: FME using different IV and topical doses of EMI-137 appeared to be safe and correctly identified 16/18 lesions, although modest target-to-background ratios were observed (median range of 1.12-1.50). C-Met overexpression varied between lesions, while physiological expression in the stomach-type epithelium was observed. Microscopically, EMI-137 accumulated around the neoplastic cell membranes. We identified several outcome parameters important for the validation of EMI-137 for FME: 1) the optimal administration route; 2) optimal dose and safety; 3) in vivo FME contrast; 4) quantification of intrinsic fluorescence; 5) ex vivo correlation of fluorescence, histopathology and target expression; and 6) microscopic tracer distribution. Conclusions: C-Met targeted FME using EMI-137 may not be the ideal combination to improve BE surveillance endoscopies, however the identified outcome parameters may serve as a valuable guidance for designing and performing future early phase clinical FME studies, independent of which fluorescent tracer is investigated.

Published
2020

2. C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies

Author

de Jongh, S.J., Voskuil, F.J., Schmidt, I., Karrenbeld, A, Kats-Ugurlu, G. (Gursah), Meersma, G.J., Westerhof, J., Witjes, MJ, van Dam, GM, Robinson, D.J. (Dominic), Nagengast, W.B., de Jongh, S.J., Voskuil, F.J., Schmidt, I., Karrenbeld, A, Kats-Ugurlu, G. (Gursah), Meersma, G.J., Westerhof, J., Witjes, MJ, van Dam, GM, Robinson, D.J. (Dominic), and Nagengast, W.B.

Abstract

Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a ‘red-flag’ endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett’s Esophagus (BE) and report several outcome parameters for early phase FME studies. Methods: FME was performed in 15 Barrett’s neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 µg/cm BE (n=1) or 100 µg/cm BE (n=4). Fluorescence was visualized in vivo, quantified in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. Results: FME using different IV and topical doses of

Published
2020
Full Text
View/download PDF

3. C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies.

Author

de Jongh SJ, Voskuil FJ, Schmidt I, Karrenbeld A, Kats-Ugurlu G, Meersma GJ, Westerhof J, Witjes MJH, van Dam GM, Robinson DJ, and Nagengast WB

Subjects
Aged, Biopsy methods, Esophageal Neoplasms genetics, Female, Humans, Male, Middle Aged, Prospective Studies, Proto-Oncogene Proteins c-met genetics, Barrett Esophagus metabolism, Esophageal Neoplasms metabolism, Proto-Oncogene Proteins c-met metabolism
Abstract

Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a 'red-flag' endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett's Esophagus (BE) and report several outcome parameters for early phase FME studies. Methods : FME was performed in 15 Barrett's neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 μg/cm BE (n=1) or 100 μg/cm BE (n=4). Fluorescence was visualized in vivo, quantified in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. Results : FME using different IV and topical doses of EMI-137 appeared to be safe and correctly identified 16/18 lesions, although modest target-to-background ratios were observed (median range of 1.12-1.50). C-Met overexpression varied between lesions, while physiological expression in the stomach-type epithelium was observed. Microscopically, EMI-137 accumulated around the neoplastic cell membranes. We identified several outcome parameters important for the validation of EMI-137 for FME: 1) the optimal administration route; 2) optimal dose and safety; 3) in vivo FME contrast; 4) quantification of intrinsic fluorescence; 5) ex vivo correlation of fluorescence, histopathology and target expression; and 6) microscopic tracer distribution. Conclusions : C-Met targeted FME using EMI-137 may not be the ideal combination to improve BE surveillance endoscopies, however the identified outcome parameters may serve as a valuable guidance for designing and performing future early phase clinical FME studies, independent of which fluorescent tracer is investigated., Competing Interests: Competing Interests: GMvD and WBN received an unrestricted research grant from SurgVision B.V. (Groningen, the Netherlands). GMvD is member of the Scientific Advisory Board of SurgVision BV, and CEO, founder and shareholder of TRACER Europe BV/AxelaRx. The other authors have declared that no competing interests exists., (© The author(s).)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results